Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are they issuing shares today? Not sure if the below authorizes them to do so?
All authorized but unissued shares of common stock will be available for issuance from time to time for any proper purpose approved by the Board of Directors (including issuances in connection with issuances to raise capital, effect acquisitions or stock-based employee benefit plans), without further vote of the stockholders, except as required under applicable law or the Nasdaq Marketplace Rules. There are currently no arrangements, agreements or understandings for the issuance of the additional shares of authorized common stock except for issuances in the ordinary course of business. The Board of Directors does not presently intend to seek further stockholder approval of any particular issuance of shares unless such approval is required by law or the Nasdaq Marketplace Rules.
I googled term sheets and found this article.
https://c.ymcdn.com/sites/www.michbio.org/resource/resmgr/BioToolBox_-_BioResearch/Biotech-Licensing-Negotiatio.pdf
It says in the press release that the warrants have anti-dilution adjustments.
Anyone think Amgen paid any exit fees to terminate the agreement?
I was wondering the same thing from a technical/trading standpoint. Once they expire do I have to do anything other than take the tax right off?
Short interest down 100k. Not that it matters
Short interest down another 336K to 3.189M
If you remember ADXS filed a confidential treatment notice so the terms weren't disclosed. MY guess is most of the $475M are sales milestones.
Short interest down another 55K
Reagan also said "Trust but Verify" when referring to the denuclearization talks. Unfortunately for Berlin he is saddled with the sins of his predecessors and needs to step up soon.
From what I read berlin gets a $150k bonus for arranging financing. Really no long term down side for him
Would the company be required to report those results of the right to try patients? If so they may not want to do that to avoid negative results for those patients too late in their stage of disease.
Short interest down to 5.2M. Down by over 3M shares
I guess the question to ask ourselves is...if you currently didn't own any ADXS, knowing everything you currently know would you buy any based on current events. I'm not buying anymore but am ready to ride it to $0. Not much more to lose.
I don't know if it matters to the price action today but the 15th is the settlement date for short interest reporting
Hey you could be sitting here in the suburbs of Chicago today. 8" of snow on the ground overnight and this am and more coming down like crazy. On the good side most people didn't go to work today.
Guess now we know why the short interest went back up.
Obviously the hope is that it would be used on patients in earlier stages of cancer at some point with much better outcomes as well. Again the trial patients had exhausted all other options and were very sick to begin with.
Short interest fell 700k
http://www.nasdaq.com/symbol/adxs/short-interest
And per Nasdaq the reporting of short interest was due in last night so if there is any change going on we won't see it for a month.
Short interest up 400k
http://www.nasdaq.com/symbol/adxs/short-interest
Your accountant is correct. If this stock never recovers there may not be enough $3000 deduction years to cover some of our losses to offset gains.
Probably a lot of harvesting going on.
Start with HR. There is at least 3 of them for 100 employees?
iggy:
The sentiment on this board is so negative that many will bail and miss any big run up once they do get back to a somewhat higher stock price based upon the recent sell the company comments... Also playing in to the manipulators hands. I have been in this since September 2010 pre reverse split no hurry to leave now.
Do you think there is some play as well to shake warrants loose too? Right now the warrants are useless when the stock is under $5.
Anyone watch "First in Human" on Discovery network hosted by Jim Parsons. Shows the NIH doing First in Human trials with some drugs. Had Car T on the first episode this week.
FDA unveils plan to eliminate orphan designation backlog
The U.S. Food and Drug Administration unveiled a strategic plan to eliminate the agency's existing orphan designation request backlog and ensure continued timely response to all new requests for designation with firm deadlines. The agency's Orphan Drug Modernization Plan comes a week after FDA Commissioner Scott Gottlieb committed to eliminating the backlog within 90 days and responding to all new requests for designation within 90 days of receipt during his testimony before a Senate subcommittee.
As authorized under the Orphan Drug Act, the Orphan Drug Designation Program provides orphan status to drugs and biologics that are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases, which are generally defined as diseases that affect fewer than 200,000 people in the United States.
Orphan designation qualifies the sponsor of the drug for various development incentives, including tax credits for clinical trial costs, relief from prescription drug user fee if the indication is for a rare disease or condition, and eligibility for seven years of marketing exclusivity upon approval. A request for orphan designation is one step that can be taken in the drug development process and is different than the filing of a marketing application with the FDA.
Currently, the FDA has about 200 orphan drug designation requests that are pending review.
The number of orphan drug designation requests has steadily increased over the past five years. In 2016, the FDA's Office of Orphan Products Development received 568 new requests for designation - more than double the number of requests received in 2012. The increased interest in the program is a positive development for those with rare diseases and under this new plan, the agency remains committed to advancing the program to ensure it can efficiently and adequately review these requests.
This is the first element of several efforts the FDA will undertake under its new "Medical Innovation Development Plan," which is aimed at ensuring that the FDA's regulatory tools and policies are modern, risk based, and efficient. The goal of the plan is to seek ways the FDA can help facilitate the development of safe, effective and transformative medical innovations that have the potential to significantly impact disease and reduce overall healthcare costs.
Among the elements of the plan to eliminate the backlog, the FDA will deploy a Backlog SWAT team comprised of senior, experienced reviewers with significant expertise in orphan drug designation. The team will focus solely on the backlogged applications, starting with the oldest requests. The agency will also employ a new streamlined Designation Review Template to increase consistency and efficiency of its reviews. The program will also look to collaborate within the agency's medical product centers to create greater efficiency, including conducting joint reviews with the Office of Pediatric Therapeutics to review rare pediatric disease designation requests.
To ensure all future requests receive a response within 90 days of receipt, the agency will take a multifaceted approach. These efforts include, among other new steps: reorganizing the review staff to maximize expertise and improve workload efficiencies; better leveraging the expertise across the FDA's medical product centers; and establishing a new FDA Orphan Products Council that will help address scientific and regulatory issues to ensure the agency is applying a consistent approach to regulating orphan drug products and reviewing designation requests.
The agency intends to communicate around the successful elimination of the backlog by mid-September and will soon provide more information about the Medical Innovation Development Plan.
FDA has the release.
Never thought of that angle. Wouldn't be surprised to see it happen
Thinking out loud. If the future is individualized therapy would a patent ever expire on that as each treatment is customized per patient?
End of Quarter too. Some fund window dressing their portfolio for end of quarter?
Amgen needs us even more now
(AP)—A unanimous Supreme Court is speeding up the time for generic biotech drugs to become available to the public in a ruling that means a loss of billions in sales to the makers of original versions.
The justices ruled today in favor of generic drug maker Sandoz in its dispute with rival Amgen over a near-copy of Amgen's cancer drug Neupogen.
The case involves biologics—drugs made from living cells instead of chemicals. The drugs have led to major advances in treating diseases but come at steep prices.
A 2010 law allows cheaper generic versions known as biosimilars to be produced after a 12-year exclusive run for the original.
Writing for the court, Justice Clarence Thomas said the law does not require companies making biosimilars to wait an extra six months after gaining Food and Drug Administration approval before selling the drugs.
The extra time can add billions of dollars in additional sales to the original drug makers before biosimilars enter the market.
The dispute involves the drug Zarxio, a generic that Sandoz developed to compete with Neupogen that sells for about 15 percent less than the original product. The drugs help boost red blood cells in cancer patients.
California-based Amgen filed a patent-infringement lawsuit alleging that Sandoz violated the 2010 Biologics Price Competition & Innovation Act. That law requires biosimilar makers to give a six-month notice of sales to rivals.
A federal appeals court sided with Amgen in 2015, ruling that the notice can't take place until after biosimilar makers gain approval from federal regulators.
Sandoz, a unit of Swiss drug giant Novartis, argued that the appeals court had it wrong and was unfairly giving an additional six months of exclusive sales to the original drugmaker.
Keeping in mind the tax man cometh and more so for short term gains unless you are trading in a Roth. My cost basis is around $5 so I would average up by trading on my core.
All of the previous trials were on the sickest of the sick that had a recurrence after other therapies. Imagine when they start the intervention earlier when the bodies immune system isn't already very weak.
Bollinger Bands-I'm betting on up
The squeeze relies on the premise that stocks fluctuate between periods of high volatility, followed by low volatility. Equities that are at six-month low levels of volatility, as demonstrated by the narrow distance between Bollinger Bands®, generally demonstrate explosive breakouts. By using non-collinear indicators, an investor or trader can determine in which direction the stock is most likely to move in the ensuing breakout. With a little practice using your favorite charting program, you should find the squeeze a welcome addition to your bag of trading tricks.
Read more: Profiting From The Bollinger Squeeze | Investopedia http://www.investopedia.com/articles/technical/04/030304.asp#ixzz4aBkQT6Ma
Follow us: Investopedia on Facebook
And the only prices that matter are the ones on the day you decide to buy or sell. Not the wishful thinking ones. I would rather see 10 posts a day with thoughtful insight rather than a hundred of gibberish.
Probably related to all of the asterisks in the 10k regarding milestones and payments.
Advaxis, Inc.
File No.1-36138 CF#34620
_____________________
Advaxis, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on January 9, 2017.
Based on representations by Advaxis, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
Exhibit 10.57 through January 9, 2027
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
google Erin Andrews Cervical Cancer
Did you see the article on Erin Andrews, cervical cancer?